S&P 500   2,466.65 (-2.38%)
DOW   20,914.98 (-2.33%)
QQQ   181.77 (-2.28%)
AAPL   240.07 (-1.98%)
FB   151.03 (-4.53%)
GOOGL   1,081.49 (-3.68%)
AMZN   1,891.91 (-1.50%)
CGC   13.44 (-2.68%)
NVDA   240.03 (-6.04%)
BABA   185.65 (-1.72%)
MU   40.82 (-0.66%)
GE   6.61 (-4.20%)
TSLA   474.30 (+4.36%)
T   27.55 (-4.21%)
ACB   0.81 (-3.58%)
F   4.20 (-3.67%)
NFLX   358.13 (-3.23%)
BAC   19.77 (-3.89%)
GILD   78.08 (+1.43%)
DIS   93.73 (-3.34%)
S&P 500   2,466.65 (-2.38%)
DOW   20,914.98 (-2.33%)
QQQ   181.77 (-2.28%)
AAPL   240.07 (-1.98%)
FB   151.03 (-4.53%)
GOOGL   1,081.49 (-3.68%)
AMZN   1,891.91 (-1.50%)
CGC   13.44 (-2.68%)
NVDA   240.03 (-6.04%)
BABA   185.65 (-1.72%)
MU   40.82 (-0.66%)
GE   6.61 (-4.20%)
TSLA   474.30 (+4.36%)
T   27.55 (-4.21%)
ACB   0.81 (-3.58%)
F   4.20 (-3.67%)
NFLX   358.13 (-3.23%)
BAC   19.77 (-3.89%)
GILD   78.08 (+1.43%)
DIS   93.73 (-3.34%)
S&P 500   2,466.65 (-2.38%)
DOW   20,914.98 (-2.33%)
QQQ   181.77 (-2.28%)
AAPL   240.07 (-1.98%)
FB   151.03 (-4.53%)
GOOGL   1,081.49 (-3.68%)
AMZN   1,891.91 (-1.50%)
CGC   13.44 (-2.68%)
NVDA   240.03 (-6.04%)
BABA   185.65 (-1.72%)
MU   40.82 (-0.66%)
GE   6.61 (-4.20%)
TSLA   474.30 (+4.36%)
T   27.55 (-4.21%)
ACB   0.81 (-3.58%)
F   4.20 (-3.67%)
NFLX   358.13 (-3.23%)
BAC   19.77 (-3.89%)
GILD   78.08 (+1.43%)
DIS   93.73 (-3.34%)
S&P 500   2,466.65 (-2.38%)
DOW   20,914.98 (-2.33%)
QQQ   181.77 (-2.28%)
AAPL   240.07 (-1.98%)
FB   151.03 (-4.53%)
GOOGL   1,081.49 (-3.68%)
AMZN   1,891.91 (-1.50%)
CGC   13.44 (-2.68%)
NVDA   240.03 (-6.04%)
BABA   185.65 (-1.72%)
MU   40.82 (-0.66%)
GE   6.61 (-4.20%)
TSLA   474.30 (+4.36%)
T   27.55 (-4.21%)
ACB   0.81 (-3.58%)
F   4.20 (-3.67%)
NFLX   358.13 (-3.23%)
BAC   19.77 (-3.89%)
GILD   78.08 (+1.43%)
DIS   93.73 (-3.34%)
Log in

NASDAQ:EVOK - Evoke Pharma Stock Price, Forecast & News

$1.02
-0.01 (-0.97 %)
(As of 04/3/2020 02:20 PM ET)
Today's Range
$1.01
Now: $1.02
$1.05
50-Day Range
$0.82
MA: $1.22
$1.52
52-Week Range
$0.50
Now: $1.02
$1.79
Volume1,085 shs
Average Volume175,150 shs
Market Capitalization$24.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.
Read More
Evoke Pharma logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVOK
CUSIPN/A
Phone858-345-1494

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.18 per share

Profitability

Net Income$-7,130,000.00

Miscellaneous

Employees6
Market Cap$24.71 million
Next Earnings Date5/13/2020 (Estimated)
OptionableNot Optionable

Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.


Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

How has Evoke Pharma's stock been impacted by COVID-19 (Coronavirus)?

Evoke Pharma's stock was trading at $1.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EVOK shares have decreased by 8.1% and is now trading at $1.02. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Evoke Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evoke Pharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Evoke Pharma.

When is Evoke Pharma's next earnings date?

Evoke Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Evoke Pharma.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma Inc (NASDAQ:EVOK) posted its quarterly earnings data on Thursday, March, 12th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.00. View Evoke Pharma's earnings history.

What are Wall Street analysts saying about Evoke Pharma stock?

Here are some recent quotes from research analysts about Evoke Pharma stock:
  • 1. According to Zacks Investment Research, "Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. " (1/4/2020)
  • 2. HC Wainwright analysts commented, "Valuation methodology and risks. We remain in a holding pattern until further clarity is obtained regarding the issues raised in the CRL and the degree to which they can be addressed near-term, as well as the timeline to potential resubmission of the Gimoti NDA and possible regulatory approval of the drug." (8/9/2019)

Has Evoke Pharma been receiving favorable news coverage?

Headlines about EVOK stock have been trending very negative on Friday, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Evoke Pharma earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutEvoke Pharma.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 235,900 shares, a decrease of 7.9% from the February 27th total of 256,100 shares. Based on an average trading volume of 196,100 shares, the short-interest ratio is presently 1.2 days. Approximately 1.1% of the shares of the stock are sold short. View Evoke Pharma's Current Options Chain.

Who are some of Evoke Pharma's key competitors?

What other stocks do shareholders of Evoke Pharma own?

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the following people:
  • Mr. David A. Gonyer, Co-Founder, CEO, Pres & Director (Age 55)
  • Mr. Matthew J. D'Onofrio, Co-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec. (Age 49)
  • Dr. Marilyn R. Carlson, Chief Medical Officer (Age 71)

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How do I buy shares of Evoke Pharma?

Shares of EVOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $1.02.

How big of a company is Evoke Pharma?

Evoke Pharma has a market capitalization of $24.71 million. The specialty pharmaceutical company earns $-7,130,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Evoke Pharma employs 6 workers across the globe. View additional information about Evoke Pharma.

What is Evoke Pharma's official website?

The official website for Evoke Pharma is http://www.evokepharma.com/.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company can be reached via phone at 858-345-1494 or via email at [email protected]


MarketBeat Community Rating for Evoke Pharma (NASDAQ EVOK)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  353 (Vote Outperform)
Underperform Votes:  227 (Vote Underperform)
Total Votes:  580
MarketBeat's community ratings are surveys of what our community members think about Evoke Pharma and other stocks. Vote "Outperform" if you believe EVOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/3/2020 by MarketBeat.com Staff

Featured Article: What is a balanced fund?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel